CorMedix (CRMD) EBITDA Margin (2013 - 2026)

CorMedix (CRMD) posted EBITDA Margin of 45.97% for Q4 2025, down 6.64% sequentially from 49.24% in Q3 2025, and up 452.0% YoY from 8.33% in Q4 2024.

CorMedix (CRMD) EBITDA Margin (2013 - 2026) Analysis & Trends

CorMedix has reported EBITDA Margin for 12 years, with the latest figure at 45.97% in Q4 2025.

Quarterly EBITDA Margin rose 452.0% year-over-year to 45.97% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 48.17% (up 9956.0% YoY) and the FY2025 annual result came in at 48.17%, up 9959.0% from the prior year.
EBITDA Margin fell to 45.97% in Q4 2025 per CRMD's latest filing, from 49.24% in the prior quarter.
Over five years, EBITDA Margin peaked at 51.5% in Q1 2025 and troughed at 102126.07% in Q3 2022.
A 4-year average of 25279.54% and a median of 8169.54% in 2021 frame the typical range for EBITDA Margin.
The widest YoY moves for EBITDA Margin: up 3304022 bps in 2022, down 8392529 bps in 2022.
Over 4 years, EBITDA Margin stood at 13794.92% in 2021, then plunged by 105 bps to 28244.66% in 2022, then soared by 100 bps to 41.45% in 2024, then grew by 11 bps to 45.97% in 2025.
According to Business Quant data, EBITDA Margin over the past three periods registered 45.97%, 49.24%, and 49.18% for Q4 2025, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	30.15%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	32.54%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	17.93%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-35.57%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	19.75%
10	CorMedix	645.20 Mn	388.51 Mn	77.13 Mn	42.10%

Download Data